{
    "info": {
        "nct_id": "NCT03217266",
        "official_title": "A Phase Ib Trial of Neoadjuvant AMG 232 (KRT-232) Concurrent With Preoperative Radiotherapy in Wild-Type P53 Soft Tissue Sarcoma (STS)",
        "inclusion_criteria": "* PRIOR TO STEP 1 REGISTRATION INCLUSION CRITERIA\n* Patients with pathologically proven diagnosis of grade 2-3 (intermediate or high grade) soft tissue sarcoma with size >= 5 cm are eligible to enroll if the intention to treat is curative. They must have sufficient tissue to submit to central laboratory for review as well as for NGS sequencing (see submission requirement). Biopsy should be obtained within 180 days prior to registration. Availability of tumor tissue is mandatory for study eligibility. The patient must have consented to provide archived formalin-fixed paraffin-embedded tumor tissue for future central pathology review, NGS sequencing and/or translational research\n* Appropriate stage for study entry based on the following diagnostic workup:\n\n  * History/physical examination within 30 days prior to registration;\n  * Imaging of the primary tumor by MRI and/or computed tomography (CT) with or without contrast and/or positron emission tomography (PET)/CT within 30 days prior to registration;\n  * Staging workup evaluated by chest CT and/or PET/CT showing no distant metastasis within 30 days prior to registration\n* There is a planned definitive surgical resection of the primary tumor\n* Eastern Cooperative Oncology Group (ECOG) or Zubrod performance status of 0-1 within 30 days prior to registration\n* Absolute neutrophil count >= 1500/uL (within 30 days prior to registration)\n* Platelet count >= 100,000/uL (within 30 days prior to registration)\n* Hemoglobin: >= 10 g/dL (transfuse as necessary to raise levels; no transfusions within 7 days of start) (within 30 days prior to registration)\n* Calculated creatinine clearance >= 60 ml/min (by Cockcroft-Gault formula) within 30 days prior to registration\n* The patient has an adequate coagulation function as defined by international normalized ratio (INR) =< 1.5 x upper limit of normal (ULN) or prothrombin time (PT) =< 1.5 x ULN, and partial thromboplastin time (PTT or aPTT) =< 1.5 x ULN (those receiving anticoagulation therapy except low molecular weight heparin are excluded) (within 30 days prior to registration)\n* Total bilirubin =< 1.5 x upper limit of normal (ULN) appropriate for age (except for patients with Gilbert's syndrome, who must have a total bilirubin < 3 mg/dL) (within 30 days prior to registration)\n* Serum glutamic-oxaloacetic transaminase (SGOT) aspartate aminotransferase (AST) or serum glutamate pyruvate transaminase (SGPT) alanine aminotransaminase (ALT) < 2.5 upper limit of normal (ULN) appropriate for age (within 30 days prior to registration)\n* Females of child-bearing potential must have a negative serum pregnancy test within 7 days prior to registration; exceptions: females not of child-bearing potential due to surgical sterilization (at least 6 weeks following tubal ligation, hysterectomy, or surgical bilateral oophorectomy with or without hysterectomy) confirmed by medical history; or female after menopause\n\n  * A \"postmenopausal woman\" is a woman meeting either of the following criteria:\n\n    * Spontaneous amenorrhea for at least 12 months, not induced by a medical condition such as anorexia nervosa and not taking medications during the amenorrhea that induced the amenorrhea (for example, oral contraceptives, hormones, gonadotropin releasing hormone, antiestrogens, selective estrogen receptor modulators [SERMs], or chemotherapy)\n    * Spontaneous amenorrhea for 6 to 12 months and a follicle-stimulating hormone (FSH) level > 40 mIU/mL\n  * Females of child-bearing potential and males must agree to use highly effective contraceptive precautions during the trial and up to 12 months following the last dose of study treatment; a highly effective method of birth control is defined as one that results in a low failure rate (that is, < 1% per year) when used consistently and correctly, such as implants, injectables, combined oral contraceptives, some intrauterine contraceptive devices (IUDs), sexual abstinence, or a vasectomized partner\n* The patient or a legally authorized representative must provide study-specific informed consent prior to study entry\n* PRIOR TO STEP 2 REGISTRATION INCLUSION CRITERIA\n* TP53 sequencing by NGS performed by central pathology lab\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* PRIOR TO STEP 1 REGISTRATION EXCLUSION CRITERIA\n* Well-differentiated liposarcoma or other low grade STS; Kaposi sarcoma, bone sarcomas, cartilage sarcomas and gastrointestinal stromal tumor (GIST)\n* Definitive clinical or radiologic evidence of metastatic disease; indeterminant lung nodules less than 8 mm are acceptable\n* The patient has history of another primary malignancy, with the exception of\n\n  * Curatively treated non-melanomatous skin cancer;\n  * Curatively treated cervical carcinoma in situ;\n  * Non-metastatic prostate cancer\n  * Other primary non-hematologic malignancies or solid tumor treated with curative intent, no known active disease, and no treatment administered during the last 3 years prior to registration\n* The patient has a serious cardiac condition, such as congestive heart failure; New York Heart Association class II/ III/IV heart disease; unstable angina pectoris, cardiac stenting within 6 months of enrollment; myocardial infarction within the last 3 months; valvulopathy that is severe, moderate, or deemed clinically significant; or arrhythmias that are symptomatic or require treatment\n* Females who are pregnant or breastfeeding\n* Prior systemic chemotherapy for the study cancer (sarcoma); note that prior chemotherapy for a different cancer is allowable; however, unresolved toxicities from prior anti-tumor therapy, defined as not having resolved to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 grade 0 or 1, or to levels dictated in the eligibility criteria with the exception of alopecia (grade 2 or 3 toxicities from prior anti-tumor therapy that are considered irreversible [defined as having been present and stable for > 6 months], such as ifosfamide-related proteinuria, may be allowed if they are not otherwise described in the exclusion criteria AND there is agreement to allow by both the investigator and sponsor)\n* Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields\n* Clinically significant bleeding within 4 weeks of screening, current use of warfarin, factor Xa inhibitors, and direct thrombin inhibitors unless these medications can be safely discontinued 14 days prior to AMG-232 (KRT-232) administration; Note: low molecular weight heparin and prophylactic low dose warfarin are permitted; PT/PTT must meet the inclusion criteria; subjects taking warfarin must have their INR followed closely\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to AMG 232 (KRT-232)\n* All subjects must agree to stop the use of all herbal medicines (e.g., St. John's wort), and supplements, within the 10 days prior to receiving the first dose of AMG 232 (KRT-232), and during the protocol AMG 232 (KRT-232) treatment (weeks 1-5); subjects may renew the use of the above at week 6; standard adult multi-vitamin is allowed\n* All subjects must agree to stop the use of any known CYP3A4 substrates with narrow therapeutic window (such as alfentanil, astemizole, cisapride, dihydroergotamine, pimozide, quinidine, sirolimus, or terfenadine; within the 14 days prior to receiving the first dose of AMG 232 (KRT-232) and during protocol AMG 232 (KRT-232) treatment (weeks 1-5); other medications (such as fentanyl and oxycodone) may be allowed per investigator's assessment/evaluation\n* All subjects must agree to stop the use of any known CYP2C8 substrates with a narrow therapeutic window within the 14 days prior to receiving the first dose of AMG 232 (KRT-232) and during protocol AMG 232 (KRT-232) treatment (weeks 1-5)\n* All subjects are required to submit a list of medications consumed within 14 days prior to receiving the first dose of AMG232 (KRT-232) and during the protocol AMG232 (KRT-232) treatment (weeks 1-5)\n* Patients with gastrointestinal (GI) tract disease causing the inability to take oral medication, malabsorption syndrome, requirement for intravenous alimentation, prior surgical procedures affecting absorption, uncontrolled inflammatory GI disease (e.g., Crohn's disease, ulcerative colitis), therefore could affect the absorption of AMG 232 (KRT-232) at the discretion of treating physician\n* Patients with active infection requiring intravenous (IV) antibiotics within 2 weeks of registration\n* Patients with known positive hepatitis B surface antigen (HepBsAg) (indicative of chronic hepatitis B), positive hepatitis total core antibody with negative HBsAG (suggestive of occult hepatitis B), or detectable hepatitis C virus RNA by a polymerase-chain reaction (PCR) assay (indicative of active hepatitis C - screening is generally done by hepatitis C antibody (HepCAb), followed by hepatitis C virus RNA by PCR if HepCAb is positive)\n* Patients known to be positive for human immunodeficiency virus (HIV) are NOT excluded from this study, but HIV-positive patients must have:\n\n  * A stable regimen of highly active anti-retroviral therapy (HAART)\n  * No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections\n  * A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard PCR-based test\n  * HIV testing is not required\n* Treatment with medications known to cause corrected QT (QTc) interval prolongation within 7 days of study day 1 is not permitted unless approved by the sponsor; use of ondansetron is permitted for treatment of nausea and vomiting",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "identified_line": {
                "line": "* Spontaneous amenorrhea for at least 12 months, not induced by a medical condition such as anorexia nervosa and not taking medications during the amenorrhea that induced the amenorrhea (for example, oral contraceptives, hormones, gonadotropin releasing hormone, antiestrogens, selective estrogen receptor modulators [SERMs], or chemotherapy)",
                "criterions": [
                    {
                        "exact_snippets": "Spontaneous amenorrhea for at least 12 months",
                        "criterion": "amenorrhea",
                        "requirement": {
                            "requirement_type": "type",
                            "expected_value": "spontaneous"
                        }
                    },
                    {
                        "exact_snippets": "Spontaneous amenorrhea for at least 12 months",
                        "criterion": "amenorrhea",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "not induced by a medical condition such as anorexia nervosa",
                        "criterion": "cause of amenorrhea",
                        "requirement": {
                            "requirement_type": "induced by medical condition",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "not taking medications during the amenorrhea that induced the amenorrhea (for example, oral contraceptives, hormones, gonadotropin releasing hormone, antiestrogens, selective estrogen receptor modulators [SERMs], or chemotherapy)",
                        "criterion": "cause of amenorrhea",
                        "requirement": {
                            "requirement_type": "induced by medication",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Spontaneous amenorrhea for at least 12 months",
                        "criterion": "amenorrhea",
                        "requirement": {
                            "requirement_type": "type",
                            "expected_value": "spontaneous"
                        }
                    },
                    {
                        "exact_snippets": "Spontaneous amenorrhea for at least 12 months",
                        "criterion": "amenorrhea",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "not induced by a medical condition such as anorexia nervosa",
                        "criterion": "cause of amenorrhea",
                        "requirement": {
                            "requirement_type": "induced by medical condition",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "not taking medications during the amenorrhea that induced the amenorrhea (for example, oral contraceptives, hormones, gonadotropin releasing hormone, antiestrogens, selective estrogen receptor modulators [SERMs], or chemotherapy)",
                        "criterion": "cause of amenorrhea",
                        "requirement": {
                            "requirement_type": "induced by medication",
                            "expected_value": false
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Females of child-bearing potential and males must agree to use highly effective contraceptive precautions during the trial and up to 12 months following the last dose of study treatment; a highly effective method of birth control is defined as one that results in a low failure rate (that is, < 1% per year) when used consistently and correctly, such as implants, injectables, combined oral contraceptives, some intrauterine contraceptive devices (IUDs), sexual abstinence, or a vasectomized partner",
                "criterions": [
                    {
                        "exact_snippets": "Females of child-bearing potential and males must agree to use highly effective contraceptive precautions during the trial and up to 12 months following the last dose of study treatment",
                        "criterion": "contraceptive use",
                        "requirement": {
                            "requirement_type": "agreement to use contraception",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Females of child-bearing potential and males must agree to use highly effective contraceptive precautions during the trial and up to 12 months following the last dose of study treatment",
                        "criterion": "contraceptive use",
                        "requirement": {
                            "requirement_type": "contraceptive method effectiveness",
                            "expected_value": {
                                "operator": "<",
                                "value": 1,
                                "unit": "% per year"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Females of child-bearing potential and males must agree to use highly effective contraceptive precautions during the trial and up to 12 months following the last dose of study treatment",
                        "criterion": "contraceptive use",
                        "requirement": {
                            "requirement_type": "contraceptive use duration",
                            "expected_value": "during the trial and up to 12 months following the last dose of study treatment"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Females of child-bearing potential and males must agree to use highly effective contraceptive precautions during the trial and up to 12 months following the last dose of study treatment",
                        "criterion": "contraceptive use",
                        "requirement": {
                            "requirement_type": "agreement to use contraception",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Females of child-bearing potential and males must agree to use highly effective contraceptive precautions during the trial and up to 12 months following the last dose of study treatment",
                        "criterion": "contraceptive use",
                        "requirement": {
                            "requirement_type": "contraceptive method effectiveness",
                            "expected_value": {
                                "operator": "<",
                                "value": 1,
                                "unit": "% per year"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Females of child-bearing potential and males must agree to use highly effective contraceptive precautions during the trial and up to 12 months following the last dose of study treatment",
                        "criterion": "contraceptive use",
                        "requirement": {
                            "requirement_type": "contraceptive use duration",
                            "expected_value": "during the trial and up to 12 months following the last dose of study treatment"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* TP53 sequencing by NGS performed by central pathology lab",
                "criterions": [
                    {
                        "exact_snippets": "TP53 sequencing by NGS performed by central pathology lab",
                        "criterion": "TP53 sequencing by NGS",
                        "requirement": {
                            "requirement_type": "performed_by",
                            "expected_value": "central pathology lab"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "TP53 sequencing by NGS performed by central pathology lab",
                        "criterion": "TP53 sequencing by NGS",
                        "requirement": {
                            "requirement_type": "performed_by",
                            "expected_value": "central pathology lab"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Patients with pathologically proven diagnosis of grade 2-3 (intermediate or high grade) soft tissue sarcoma with size >= 5 cm are eligible to enroll if the intention to treat is curative. They must have sufficient tissue to submit to central laboratory for review as well as for NGS sequencing (see submission requirement). Biopsy should be obtained within 180 days prior to registration. Availability of tumor tissue is mandatory for study eligibility. The patient must have consented to provide archived formalin-fixed paraffin-embedded tumor tissue for future central pathology review, NGS sequencing and/or translational research",
                "criterions": [
                    {
                        "exact_snippets": "pathologically proven diagnosis of grade 2-3 (intermediate or high grade) soft tissue sarcoma",
                        "criterion": "soft tissue sarcoma grade",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "pathologically proven diagnosis of grade 2-3 (intermediate or high grade) soft tissue sarcoma",
                        "criterion": "soft tissue sarcoma grade",
                        "requirement": {
                            "requirement_type": "grade",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 2,
                                        "unit": ""
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": ""
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "soft tissue sarcoma with size >= 5 cm",
                        "criterion": "soft tissue sarcoma size",
                        "requirement": {
                            "requirement_type": "size",
                            "expected_value": {
                                "operator": ">=",
                                "value": 5,
                                "unit": "cm"
                            }
                        }
                    },
                    {
                        "exact_snippets": "intention to treat is curative",
                        "criterion": "treatment intention",
                        "requirement": {
                            "requirement_type": "intention",
                            "expected_value": "curative"
                        }
                    },
                    {
                        "exact_snippets": "sufficient tissue to submit to central laboratory for review as well as for NGS sequencing",
                        "criterion": "tumor tissue for laboratory review and NGS sequencing",
                        "requirement": {
                            "requirement_type": "sufficiency",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Biopsy should be obtained within 180 days prior to registration",
                        "criterion": "biopsy timing",
                        "requirement": {
                            "requirement_type": "time since biopsy",
                            "expected_value": {
                                "operator": "<=",
                                "value": 180,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Availability of tumor tissue is mandatory for study eligibility",
                        "criterion": "tumor tissue availability",
                        "requirement": {
                            "requirement_type": "availability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "consented to provide archived formalin-fixed paraffin-embedded tumor tissue for future central pathology review, NGS sequencing and/or translational research",
                        "criterion": "consent for archived tumor tissue use",
                        "requirement": {
                            "requirement_type": "consent",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "consented to provide archived formalin-fixed paraffin-embedded tumor tissue for future central pathology review, NGS sequencing and/or translational research",
                        "criterion": "consent for archived tumor tissue use",
                        "requirement": {
                            "requirement_type": "tissue type",
                            "expected_value": "archived formalin-fixed paraffin-embedded tumor tissue"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "pathologically proven diagnosis of grade 2-3 (intermediate or high grade) soft tissue sarcoma",
                        "criterion": "soft tissue sarcoma grade",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "pathologically proven diagnosis of grade 2-3 (intermediate or high grade) soft tissue sarcoma",
                        "criterion": "soft tissue sarcoma grade",
                        "requirement": {
                            "requirement_type": "grade",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 2,
                                        "unit": ""
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": ""
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "soft tissue sarcoma with size >= 5 cm",
                        "criterion": "soft tissue sarcoma size",
                        "requirement": {
                            "requirement_type": "size",
                            "expected_value": {
                                "operator": ">=",
                                "value": 5,
                                "unit": "cm"
                            }
                        }
                    },
                    {
                        "exact_snippets": "intention to treat is curative",
                        "criterion": "treatment intention",
                        "requirement": {
                            "requirement_type": "intention",
                            "expected_value": "curative"
                        }
                    },
                    {
                        "exact_snippets": "sufficient tissue to submit to central laboratory for review as well as for NGS sequencing",
                        "criterion": "tumor tissue for laboratory review and NGS sequencing",
                        "requirement": {
                            "requirement_type": "sufficiency",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Biopsy should be obtained within 180 days prior to registration",
                        "criterion": "biopsy timing",
                        "requirement": {
                            "requirement_type": "time since biopsy",
                            "expected_value": {
                                "operator": "<=",
                                "value": 180,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Availability of tumor tissue is mandatory for study eligibility",
                        "criterion": "tumor tissue availability",
                        "requirement": {
                            "requirement_type": "availability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "consented to provide archived formalin-fixed paraffin-embedded tumor tissue for future central pathology review, NGS sequencing and/or translational research",
                        "criterion": "consent for archived tumor tissue use",
                        "requirement": {
                            "requirement_type": "consent",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "consented to provide archived formalin-fixed paraffin-embedded tumor tissue for future central pathology review, NGS sequencing and/or translational research",
                        "criterion": "consent for archived tumor tissue use",
                        "requirement": {
                            "requirement_type": "tissue type",
                            "expected_value": "archived formalin-fixed paraffin-embedded tumor tissue"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Spontaneous amenorrhea for 6 to 12 months and a follicle-stimulating hormone (FSH) level > 40 mIU/mL",
                "criterions": [
                    {
                        "exact_snippets": "Spontaneous amenorrhea for 6 to 12 months",
                        "criterion": "spontaneous amenorrhea",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 6,
                                        "unit": "months"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 12,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "follicle-stimulating hormone (FSH) level > 40 mIU/mL",
                        "criterion": "follicle-stimulating hormone (FSH) level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 40,
                                "unit": "mIU/mL"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Spontaneous amenorrhea for 6 to 12 months",
                        "criterion": "spontaneous amenorrhea",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 6,
                                        "unit": "months"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 12,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "follicle-stimulating hormone (FSH) level > 40 mIU/mL",
                        "criterion": "follicle-stimulating hormone (FSH) level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 40,
                                "unit": "mIU/mL"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* History/physical examination within 30 days prior to registration;",
                "criterions": [
                    {
                        "exact_snippets": "History/physical examination within 30 days prior to registration",
                        "criterion": "history and physical examination",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days prior to registration"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "History/physical examination within 30 days prior to registration",
                        "criterion": "history and physical examination",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days prior to registration"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* The patient has an adequate coagulation function as defined by international normalized ratio (INR) =< 1.5 x upper limit of normal (ULN) or prothrombin time (PT) =< 1.5 x ULN, and partial thromboplastin time (PTT or aPTT) =< 1.5 x ULN (those receiving anticoagulation therapy except low molecular weight heparin are excluded) (within 30 days prior to registration)",
                "criterions": [
                    {
                        "exact_snippets": "international normalized ratio (INR) =< 1.5 x upper limit of normal (ULN)",
                        "criterion": "international normalized ratio (INR)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "prothrombin time (PT) =< 1.5 x ULN",
                        "criterion": "prothrombin time (PT)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "partial thromboplastin time (PTT or aPTT) =< 1.5 x ULN",
                        "criterion": "partial thromboplastin time (PTT or aPTT)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "those receiving anticoagulation therapy except low molecular weight heparin are excluded",
                        "criterion": "anticoagulation therapy (except low molecular weight heparin)",
                        "requirement": {
                            "requirement_type": "exclusion",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "within 30 days prior to registration",
                        "criterion": "timing of laboratory tests",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": "within 30 days prior to registration"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "or_criteria": [
                                    {
                                        "exact_snippets": "international normalized ratio (INR) =< 1.5 x upper limit of normal (ULN)",
                                        "criterion": "international normalized ratio (INR)",
                                        "requirement": {
                                            "requirement_type": "quantity",
                                            "expected_value": {
                                                "operator": "<=",
                                                "value": 1.5,
                                                "unit": "x ULN"
                                            }
                                        }
                                    },
                                    {
                                        "exact_snippets": "prothrombin time (PT) =< 1.5 x ULN",
                                        "criterion": "prothrombin time (PT)",
                                        "requirement": {
                                            "requirement_type": "quantity",
                                            "expected_value": {
                                                "operator": "<=",
                                                "value": 1.5,
                                                "unit": "x ULN"
                                            }
                                        }
                                    }
                                ]
                            },
                            {
                                "exact_snippets": "partial thromboplastin time (PTT or aPTT) =< 1.5 x ULN",
                                "criterion": "partial thromboplastin time (PTT or aPTT)",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 1.5,
                                        "unit": "x ULN"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "those receiving anticoagulation therapy except low molecular weight heparin are excluded",
                        "criterion": "anticoagulation therapy (except low molecular weight heparin)",
                        "requirement": {
                            "requirement_type": "exclusion",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "within 30 days prior to registration",
                        "criterion": "timing of laboratory tests",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": "within 30 days prior to registration"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Absolute neutrophil count >= 1500/uL (within 30 days prior to registration)",
                "criterions": [
                    {
                        "exact_snippets": "Absolute neutrophil count >= 1500/uL",
                        "criterion": "absolute neutrophil count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1500,
                                "unit": "uL"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Absolute neutrophil count >= 1500/uL",
                        "criterion": "absolute neutrophil count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1500,
                                "unit": "uL"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PRIOR TO STEP 2 REGISTRATION INCLUSION CRITERIA",
                "criterions": [
                    {
                        "exact_snippets": "PRIOR TO STEP 2 REGISTRATION INCLUSION CRITERIA",
                        "criterion": "step 2 registration inclusion criteria",
                        "requirement": {
                            "requirement_type": "applicability",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "PRIOR TO STEP 2 REGISTRATION INCLUSION CRITERIA",
                        "criterion": "step 2 registration inclusion criteria",
                        "requirement": {
                            "requirement_type": "applicability",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Platelet count >= 100,000/uL (within 30 days prior to registration)",
                "criterions": [
                    {
                        "exact_snippets": "Platelet count >= 100,000/uL (within 30 days prior to registration)",
                        "criterion": "platelet count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100000,
                                "unit": "uL"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Platelet count >= 100,000/uL (within 30 days prior to registration)",
                        "criterion": "platelet count",
                        "requirement": {
                            "requirement_type": "time frame",
                            "expected_value": "within 30 days prior to registration"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Platelet count >= 100,000/uL (within 30 days prior to registration)",
                        "criterion": "platelet count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100000,
                                "unit": "uL"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Platelet count >= 100,000/uL (within 30 days prior to registration)",
                        "criterion": "platelet count",
                        "requirement": {
                            "requirement_type": "time frame",
                            "expected_value": "within 30 days prior to registration"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* A \"postmenopausal woman\" is a woman meeting either of the following criteria:",
                "criterions": [
                    {
                        "exact_snippets": "\"postmenopausal woman\" is a woman",
                        "criterion": "sex",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": "female"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "\"postmenopausal woman\" is a woman",
                        "criterion": "sex",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": "female"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* The patient or a legally authorized representative must provide study-specific informed consent prior to study entry",
                "criterions": [
                    {
                        "exact_snippets": "The patient or a legally authorized representative must provide study-specific informed consent prior to study entry",
                        "criterion": "informed consent",
                        "requirement": {
                            "requirement_type": "provision",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "The patient or a legally authorized representative must provide study-specific informed consent prior to study entry",
                        "criterion": "informed consent",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "prior to study entry"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "The patient or a legally authorized representative must provide study-specific informed consent prior to study entry",
                        "criterion": "informed consent",
                        "requirement": {
                            "requirement_type": "provision",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "The patient or a legally authorized representative must provide study-specific informed consent prior to study entry",
                        "criterion": "informed consent",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "prior to study entry"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Eastern Cooperative Oncology Group (ECOG) or Zubrod performance status of 0-1 within 30 days prior to registration",
                "criterions": [
                    {
                        "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) or Zubrod performance status of 0-1",
                        "criterion": "performance status (ECOG or Zubrod)",
                        "requirement": {
                            "requirement_type": "score",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": ""
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": ""
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "within 30 days prior to registration",
                        "criterion": "performance status assessment timing",
                        "requirement": {
                            "requirement_type": "time before registration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) or Zubrod performance status of 0-1",
                        "criterion": "performance status (ECOG or Zubrod)",
                        "requirement": {
                            "requirement_type": "score",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": ""
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": ""
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "within 30 days prior to registration",
                        "criterion": "performance status assessment timing",
                        "requirement": {
                            "requirement_type": "time before registration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Calculated creatinine clearance >= 60 ml/min (by Cockcroft-Gault formula) within 30 days prior to registration",
                "criterions": [
                    {
                        "exact_snippets": "Calculated creatinine clearance >= 60 ml/min (by Cockcroft-Gault formula) within 30 days prior to registration",
                        "criterion": "calculated creatinine clearance",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 60,
                                "unit": "ml/min"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Calculated creatinine clearance >= 60 ml/min (by Cockcroft-Gault formula) within 30 days prior to registration",
                        "criterion": "calculated creatinine clearance",
                        "requirement": {
                            "requirement_type": "calculation method",
                            "expected_value": "Cockcroft-Gault formula"
                        }
                    },
                    {
                        "exact_snippets": "Calculated creatinine clearance >= 60 ml/min (by Cockcroft-Gault formula) within 30 days prior to registration",
                        "criterion": "calculated creatinine clearance",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": "within 30 days prior to registration"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Calculated creatinine clearance >= 60 ml/min (by Cockcroft-Gault formula) within 30 days prior to registration",
                        "criterion": "calculated creatinine clearance",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 60,
                                "unit": "ml/min"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Calculated creatinine clearance >= 60 ml/min (by Cockcroft-Gault formula) within 30 days prior to registration",
                        "criterion": "calculated creatinine clearance",
                        "requirement": {
                            "requirement_type": "calculation method",
                            "expected_value": "Cockcroft-Gault formula"
                        }
                    },
                    {
                        "exact_snippets": "Calculated creatinine clearance >= 60 ml/min (by Cockcroft-Gault formula) within 30 days prior to registration",
                        "criterion": "calculated creatinine clearance",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": "within 30 days prior to registration"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Must have minimum age of 18 Years",
                "criterions": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Healthy volunteers allowed",
                "criterions": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Appropriate stage for study entry based on the following diagnostic workup:",
                "criterions": [
                    {
                        "exact_snippets": "Appropriate stage for study entry",
                        "criterion": "disease stage",
                        "requirement": {
                            "requirement_type": "appropriateness for study entry",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Appropriate stage for study entry",
                        "criterion": "disease stage",
                        "requirement": {
                            "requirement_type": "appropriateness for study entry",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Hemoglobin: >= 10 g/dL (transfuse as necessary to raise levels; no transfusions within 7 days of start) (within 30 days prior to registration)",
                "criterions": [
                    {
                        "exact_snippets": "Hemoglobin: >= 10 g/dL",
                        "criterion": "hemoglobin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 10,
                                "unit": "g/dL"
                            }
                        }
                    },
                    {
                        "exact_snippets": "no transfusions within 7 days of start",
                        "criterion": "blood transfusion",
                        "requirement": {
                            "requirement_type": "absence within time window",
                            "expected_value": "no transfusions within 7 days of start"
                        }
                    },
                    {
                        "exact_snippets": "within 30 days prior to registration",
                        "criterion": "hemoglobin measurement timing",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": "within 30 days prior to registration"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Hemoglobin: >= 10 g/dL",
                        "criterion": "hemoglobin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 10,
                                "unit": "g/dL"
                            }
                        }
                    },
                    {
                        "exact_snippets": "no transfusions within 7 days of start",
                        "criterion": "blood transfusion",
                        "requirement": {
                            "requirement_type": "absence within time window",
                            "expected_value": "no transfusions within 7 days of start"
                        }
                    },
                    {
                        "exact_snippets": "within 30 days prior to registration",
                        "criterion": "hemoglobin measurement timing",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": "within 30 days prior to registration"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PRIOR TO STEP 1 REGISTRATION INCLUSION CRITERIA",
                "criterions": [
                    {
                        "exact_snippets": "PRIOR TO STEP 1 REGISTRATION INCLUSION CRITERIA",
                        "criterion": "step 1 registration inclusion criteria",
                        "requirement": {
                            "requirement_type": "applicability",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "PRIOR TO STEP 1 REGISTRATION INCLUSION CRITERIA",
                        "criterion": "step 1 registration inclusion criteria",
                        "requirement": {
                            "requirement_type": "applicability",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Total bilirubin =< 1.5 x upper limit of normal (ULN) appropriate for age (except for patients with Gilbert's syndrome, who must have a total bilirubin < 3 mg/dL) (within 30 days prior to registration)",
                "criterions": [
                    {
                        "exact_snippets": "Total bilirubin =< 1.5 x upper limit of normal (ULN) appropriate for age (except for patients with Gilbert's syndrome, who must have a total bilirubin < 3 mg/dL)",
                        "criterion": "total bilirubin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 1.5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "except for patients with Gilbert's syndrome, who must have a total bilirubin < 3 mg/dL",
                        "criterion": "total bilirubin in patients with Gilbert's syndrome",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<",
                                        "value": 3,
                                        "unit": "mg/dL"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "condition": {
                    "exact_snippets": "except for patients with Gilbert's syndrome, who must have a total bilirubin < 3 mg/dL",
                    "criterion": "total bilirubin in patients with Gilbert's syndrome",
                    "requirement": {
                        "requirement_type": "quantity",
                        "expected_value": {
                            "comparisons": [
                                {
                                    "operator": "<",
                                    "value": 3,
                                    "unit": "mg/dL"
                                }
                            ]
                        }
                    }
                },
                "then_criteria": null,
                "else_criteria": {
                    "exact_snippets": "Total bilirubin =< 1.5 x upper limit of normal (ULN) appropriate for age (except for patients with Gilbert's syndrome, who must have a total bilirubin < 3 mg/dL)",
                    "criterion": "total bilirubin",
                    "requirement": {
                        "requirement_type": "quantity",
                        "expected_value": {
                            "comparisons": [
                                {
                                    "operator": "<=",
                                    "value": 1.5,
                                    "unit": "x ULN"
                                }
                            ]
                        }
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "* There is a planned definitive surgical resection of the primary tumor",
                "criterions": [
                    {
                        "exact_snippets": "planned definitive surgical resection of the primary tumor",
                        "criterion": "definitive surgical resection of the primary tumor",
                        "requirement": {
                            "requirement_type": "planned",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "planned definitive surgical resection of the primary tumor",
                        "criterion": "definitive surgical resection of the primary tumor",
                        "requirement": {
                            "requirement_type": "planned",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Serum glutamic-oxaloacetic transaminase (SGOT) aspartate aminotransferase (AST) or serum glutamate pyruvate transaminase (SGPT) alanine aminotransaminase (ALT) < 2.5 upper limit of normal (ULN) appropriate for age (within 30 days prior to registration)",
                "criterions": [
                    {
                        "exact_snippets": "Serum glutamic-oxaloacetic transaminase (SGOT) aspartate aminotransferase (AST) ... < 2.5 upper limit of normal (ULN) appropriate for age (within 30 days prior to registration)",
                        "criterion": "aspartate aminotransferase (AST) level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 2.5,
                                "unit": "ULN appropriate for age"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Serum glutamic-oxaloacetic transaminase (SGOT) aspartate aminotransferase (AST) ... < 2.5 upper limit of normal (ULN) appropriate for age (within 30 days prior to registration)",
                        "criterion": "aspartate aminotransferase (AST) level",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": "within 30 days prior to registration"
                        }
                    },
                    {
                        "exact_snippets": "serum glutamate pyruvate transaminase (SGPT) alanine aminotransaminase (ALT) < 2.5 upper limit of normal (ULN) appropriate for age (within 30 days prior to registration)",
                        "criterion": "alanine aminotransferase (ALT) level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 2.5,
                                "unit": "ULN appropriate for age"
                            }
                        }
                    },
                    {
                        "exact_snippets": "serum glutamate pyruvate transaminase (SGPT) alanine aminotransaminase (ALT) < 2.5 upper limit of normal (ULN) appropriate for age (within 30 days prior to registration)",
                        "criterion": "alanine aminotransferase (ALT) level",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": "within 30 days prior to registration"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Serum glutamic-oxaloacetic transaminase (SGOT) aspartate aminotransferase (AST) ... < 2.5 upper limit of normal (ULN) appropriate for age (within 30 days prior to registration)",
                                "criterion": "aspartate aminotransferase (AST) level",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "operator": "<",
                                        "value": 2.5,
                                        "unit": "ULN appropriate for age"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "Serum glutamic-oxaloacetic transaminase (SGOT) aspartate aminotransferase (AST) ... < 2.5 upper limit of normal (ULN) appropriate for age (within 30 days prior to registration)",
                                "criterion": "aspartate aminotransferase (AST) level",
                                "requirement": {
                                    "requirement_type": "time window",
                                    "expected_value": "within 30 days prior to registration"
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "serum glutamate pyruvate transaminase (SGPT) alanine aminotransaminase (ALT) < 2.5 upper limit of normal (ULN) appropriate for age (within 30 days prior to registration)",
                                "criterion": "alanine aminotransferase (ALT) level",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "operator": "<",
                                        "value": 2.5,
                                        "unit": "ULN appropriate for age"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "serum glutamate pyruvate transaminase (SGPT) alanine aminotransaminase (ALT) < 2.5 upper limit of normal (ULN) appropriate for age (within 30 days prior to registration)",
                                "criterion": "alanine aminotransferase (ALT) level",
                                "requirement": {
                                    "requirement_type": "time window",
                                    "expected_value": "within 30 days prior to registration"
                                }
                            }
                        ]
                    }
                ]
            }
        }
    ],
    "exclusion_lines": [
        {
            "identified_line": {
                "line": "* Patients with known positive hepatitis B surface antigen (HepBsAg) (indicative of chronic hepatitis B), positive hepatitis total core antibody with negative HBsAG (suggestive of occult hepatitis B), or detectable hepatitis C virus RNA by a polymerase-chain reaction (PCR) assay (indicative of active hepatitis C - screening is generally done by hepatitis C antibody (HepCAb), followed by hepatitis C virus RNA by PCR if HepCAb is positive)",
                "criterions": [
                    {
                        "exact_snippets": "known positive hepatitis B surface antigen (HepBsAg) (indicative of chronic hepatitis B)",
                        "criterion": "hepatitis B surface antigen (HepBsAg)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "positive hepatitis total core antibody with negative HBsAG (suggestive of occult hepatitis B)",
                        "criterion": "hepatitis total core antibody and hepatitis B surface antigen (HepBsAg)",
                        "requirement": {
                            "requirement_type": "hepatitis total core antibody presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "positive hepatitis total core antibody with negative HBsAG (suggestive of occult hepatitis B)",
                        "criterion": "hepatitis total core antibody and hepatitis B surface antigen (HepBsAg)",
                        "requirement": {
                            "requirement_type": "hepatitis B surface antigen (HepBsAg) presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "detectable hepatitis C virus RNA by a polymerase-chain reaction (PCR) assay (indicative of active hepatitis C",
                        "criterion": "hepatitis C virus RNA by PCR",
                        "requirement": {
                            "requirement_type": "detectable",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "known positive hepatitis B surface antigen (HepBsAg) (indicative of chronic hepatitis B)",
                        "criterion": "hepatitis B surface antigen (HepBsAg)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "positive hepatitis total core antibody with negative HBsAG (suggestive of occult hepatitis B)",
                                "criterion": "hepatitis total core antibody and hepatitis B surface antigen (HepBsAg)",
                                "requirement": {
                                    "requirement_type": "hepatitis total core antibody presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "positive hepatitis total core antibody with negative HBsAG (suggestive of occult hepatitis B)",
                                "criterion": "hepatitis total core antibody and hepatitis B surface antigen (HepBsAg)",
                                "requirement": {
                                    "requirement_type": "hepatitis B surface antigen (HepBsAg) presence",
                                    "expected_value": false
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "detectable hepatitis C virus RNA by a polymerase-chain reaction (PCR) assay (indicative of active hepatitis C",
                        "criterion": "hepatitis C virus RNA by PCR",
                        "requirement": {
                            "requirement_type": "detectable",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* A stable regimen of highly active anti-retroviral therapy (HAART)",
                "criterions": [
                    {
                        "exact_snippets": "A stable regimen of highly active anti-retroviral therapy (HAART)",
                        "criterion": "highly active anti-retroviral therapy (HAART) regimen",
                        "requirement": {
                            "requirement_type": "stability",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "A stable regimen of highly active anti-retroviral therapy (HAART)",
                    "criterion": "highly active anti-retroviral therapy (HAART) regimen",
                    "requirement": {
                        "requirement_type": "stability",
                        "expected_value": true
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "* Non-metastatic prostate cancer",
                "criterions": [
                    {
                        "exact_snippets": "Non-metastatic prostate cancer",
                        "criterion": "prostate cancer",
                        "requirement": {
                            "requirement_type": "metastatic status",
                            "expected_value": "non-metastatic"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Non-metastatic prostate cancer",
                        "criterion": "prostate cancer",
                        "requirement": {
                            "requirement_type": "metastatic status",
                            "expected_value": "non-metastatic"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Well-differentiated liposarcoma or other low grade STS; Kaposi sarcoma, bone sarcomas, cartilage sarcomas and gastrointestinal stromal tumor (GIST)",
                "criterions": [
                    {
                        "exact_snippets": "Well-differentiated liposarcoma",
                        "criterion": "well-differentiated liposarcoma",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "other low grade STS",
                        "criterion": "low grade soft tissue sarcoma (STS)",
                        "requirement": {
                            "requirement_type": "grade",
                            "expected_value": "low"
                        }
                    },
                    {
                        "exact_snippets": "other low grade STS",
                        "criterion": "low grade soft tissue sarcoma (STS)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Kaposi sarcoma",
                        "criterion": "Kaposi sarcoma",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "bone sarcomas",
                        "criterion": "bone sarcoma",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "cartilage sarcomas",
                        "criterion": "cartilage sarcoma",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "gastrointestinal stromal tumor (GIST)",
                        "criterion": "gastrointestinal stromal tumor (GIST)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Well-differentiated liposarcoma",
                        "criterion": "well-differentiated liposarcoma",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "other low grade STS",
                                "criterion": "low grade soft tissue sarcoma (STS)",
                                "requirement": {
                                    "requirement_type": "grade",
                                    "expected_value": "low"
                                }
                            },
                            {
                                "exact_snippets": "other low grade STS",
                                "criterion": "low grade soft tissue sarcoma (STS)",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "Kaposi sarcoma",
                        "criterion": "Kaposi sarcoma",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "bone sarcomas",
                        "criterion": "bone sarcoma",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "cartilage sarcomas",
                        "criterion": "cartilage sarcoma",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "gastrointestinal stromal tumor (GIST)",
                        "criterion": "gastrointestinal stromal tumor (GIST)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* All subjects are required to submit a list of medications consumed within 14 days prior to receiving the first dose of AMG232 (KRT-232) and during the protocol AMG232 (KRT-232) treatment (weeks 1-5)",
                "criterions": [
                    {
                        "exact_snippets": "All subjects are required to submit a list of medications consumed within 14 days prior to receiving the first dose of AMG232 (KRT-232)",
                        "criterion": "medication list submission (pre-treatment)",
                        "requirement": {
                            "requirement_type": "submission",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "All subjects are required to submit a list of medications consumed within 14 days prior to receiving the first dose of AMG232 (KRT-232)",
                        "criterion": "medication list submission (pre-treatment)",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days before first dose"
                            }
                        }
                    },
                    {
                        "exact_snippets": "submit a list of medications consumed ... during the protocol AMG232 (KRT-232) treatment (weeks 1-5)",
                        "criterion": "medication list submission (during treatment)",
                        "requirement": {
                            "requirement_type": "submission",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "submit a list of medications consumed ... during the protocol AMG232 (KRT-232) treatment (weeks 1-5)",
                        "criterion": "medication list submission (during treatment)",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "week"
                            }
                        }
                    },
                    {
                        "exact_snippets": "submit a list of medications consumed ... during the protocol AMG232 (KRT-232) treatment (weeks 1-5)",
                        "criterion": "medication list submission (during treatment)",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5,
                                "unit": "weeks"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "All subjects are required to submit a list of medications consumed within 14 days prior to receiving the first dose of AMG232 (KRT-232)",
                                "criterion": "medication list submission (pre-treatment)",
                                "requirement": {
                                    "requirement_type": "submission",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "All subjects are required to submit a list of medications consumed within 14 days prior to receiving the first dose of AMG232 (KRT-232)",
                                "criterion": "medication list submission (pre-treatment)",
                                "requirement": {
                                    "requirement_type": "time window",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 14,
                                        "unit": "days before first dose"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "submit a list of medications consumed ... during the protocol AMG232 (KRT-232) treatment (weeks 1-5)",
                                "criterion": "medication list submission (during treatment)",
                                "requirement": {
                                    "requirement_type": "submission",
                                    "expected_value": true
                                }
                            },
                            {
                                "and_criteria": [
                                    {
                                        "exact_snippets": "submit a list of medications consumed ... during the protocol AMG232 (KRT-232) treatment (weeks 1-5)",
                                        "criterion": "medication list submission (during treatment)",
                                        "requirement": {
                                            "requirement_type": "time window",
                                            "expected_value": {
                                                "operator": ">=",
                                                "value": 1,
                                                "unit": "week"
                                            }
                                        }
                                    },
                                    {
                                        "exact_snippets": "submit a list of medications consumed ... during the protocol AMG232 (KRT-232) treatment (weeks 1-5)",
                                        "criterion": "medication list submission (during treatment)",
                                        "requirement": {
                                            "requirement_type": "time window",
                                            "expected_value": {
                                                "operator": "<=",
                                                "value": 5,
                                                "unit": "weeks"
                                            }
                                        }
                                    }
                                ]
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Curatively treated cervical carcinoma in situ;",
                "criterions": [
                    {
                        "exact_snippets": "Curatively treated cervical carcinoma in situ",
                        "criterion": "cervical carcinoma in situ",
                        "requirement": {
                            "requirement_type": "treatment status",
                            "expected_value": "curatively treated"
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Curatively treated cervical carcinoma in situ",
                    "criterion": "cervical carcinoma in situ",
                    "requirement": {
                        "requirement_type": "treatment status",
                        "expected_value": "curatively treated"
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections",
                "criterions": [
                    {
                        "exact_snippets": "No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections",
                        "criterion": "requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections",
                        "requirement": {
                            "requirement_type": "requirement",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections",
                        "criterion": "requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections",
                        "requirement": {
                            "requirement_type": "requirement",
                            "expected_value": false
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* The patient has history of another primary malignancy, with the exception of",
                "criterions": [
                    {
                        "exact_snippets": "history of another primary malignancy",
                        "criterion": "history of another primary malignancy",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "history of another primary malignancy",
                        "criterion": "history of another primary malignancy",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Curatively treated non-melanomatous skin cancer;",
                "criterions": [
                    {
                        "exact_snippets": "Curatively treated non-melanomatous skin cancer",
                        "criterion": "non-melanomatous skin cancer",
                        "requirement": {
                            "requirement_type": "treatment status",
                            "expected_value": "curatively treated"
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Curatively treated non-melanomatous skin cancer",
                    "criterion": "non-melanomatous skin cancer",
                    "requirement": {
                        "requirement_type": "treatment status",
                        "expected_value": "curatively treated"
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "* Patients with active infection requiring intravenous (IV) antibiotics within 2 weeks of registration",
                "criterions": [
                    {
                        "exact_snippets": "active infection requiring intravenous (IV) antibiotics within 2 weeks of registration",
                        "criterion": "active infection",
                        "requirement": {
                            "requirement_type": "treatment requirement",
                            "expected_value": "requiring intravenous (IV) antibiotics"
                        }
                    },
                    {
                        "exact_snippets": "active infection requiring intravenous (IV) antibiotics within 2 weeks of registration",
                        "criterion": "active infection",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks before registration"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "active infection requiring intravenous (IV) antibiotics within 2 weeks of registration",
                        "criterion": "active infection",
                        "requirement": {
                            "requirement_type": "treatment requirement",
                            "expected_value": "requiring intravenous (IV) antibiotics"
                        }
                    },
                    {
                        "exact_snippets": "active infection requiring intravenous (IV) antibiotics within 2 weeks of registration",
                        "criterion": "active infection",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks before registration"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Patients known to be positive for human immunodeficiency virus (HIV) are NOT excluded from this study, but HIV-positive patients must have:",
                "criterions": [
                    {
                        "exact_snippets": "Patients known to be positive for human immunodeficiency virus (HIV)",
                        "criterion": "HIV status",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "condition": {
                    "exact_snippets": "Patients known to be positive for human immunodeficiency virus (HIV)",
                    "criterion": "HIV status",
                    "requirement": {
                        "requirement_type": "presence",
                        "expected_value": true
                    }
                },
                "then_criteria": null,
                "else_criteria": null
            }
        },
        {
            "identified_line": {
                "line": "* Patients with gastrointestinal (GI) tract disease causing the inability to take oral medication, malabsorption syndrome, requirement for intravenous alimentation, prior surgical procedures affecting absorption, uncontrolled inflammatory GI disease (e.g., Crohn's disease, ulcerative colitis), therefore could affect the absorption of AMG 232 (KRT-232) at the discretion of treating physician",
                "criterions": [
                    {
                        "exact_snippets": "gastrointestinal (GI) tract disease causing the inability to take oral medication",
                        "criterion": "gastrointestinal tract disease",
                        "requirement": {
                            "requirement_type": "effect",
                            "expected_value": "causing inability to take oral medication"
                        }
                    },
                    {
                        "exact_snippets": "malabsorption syndrome",
                        "criterion": "malabsorption syndrome",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "requirement for intravenous alimentation",
                        "criterion": "requirement for intravenous alimentation",
                        "requirement": {
                            "requirement_type": "requirement",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "prior surgical procedures affecting absorption",
                        "criterion": "prior surgical procedures affecting absorption",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "uncontrolled inflammatory GI disease (e.g., Crohn's disease, ulcerative colitis)",
                        "criterion": "uncontrolled inflammatory gastrointestinal disease",
                        "requirement": {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "gastrointestinal (GI) tract disease causing the inability to take oral medication",
                        "criterion": "gastrointestinal tract disease",
                        "requirement": {
                            "requirement_type": "effect",
                            "expected_value": "causing inability to take oral medication"
                        }
                    },
                    {
                        "exact_snippets": "malabsorption syndrome",
                        "criterion": "malabsorption syndrome",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "requirement for intravenous alimentation",
                        "criterion": "requirement for intravenous alimentation",
                        "requirement": {
                            "requirement_type": "requirement",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "prior surgical procedures affecting absorption",
                        "criterion": "prior surgical procedures affecting absorption",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "uncontrolled inflammatory GI disease (e.g., Crohn's disease, ulcerative colitis)",
                        "criterion": "uncontrolled inflammatory gastrointestinal disease",
                        "requirement": {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Other primary non-hematologic malignancies or solid tumor treated with curative intent, no known active disease, and no treatment administered during the last 3 years prior to registration",
                "criterions": [
                    {
                        "exact_snippets": "Other primary non-hematologic malignancies or solid tumor",
                        "criterion": "other primary non-hematologic malignancy or solid tumor",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "treated with curative intent",
                        "criterion": "treatment intent for other primary non-hematologic malignancy or solid tumor",
                        "requirement": {
                            "requirement_type": "treatment_intent",
                            "expected_value": "curative"
                        }
                    },
                    {
                        "exact_snippets": "no known active disease",
                        "criterion": "active disease status of other primary non-hematologic malignancy or solid tumor",
                        "requirement": {
                            "requirement_type": "active_disease",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "no treatment administered during the last 3 years prior to registration",
                        "criterion": "recent treatment for other primary non-hematologic malignancy or solid tumor",
                        "requirement": {
                            "requirement_type": "treatment_within_timeframe",
                            "expected_value": {
                                "operator": "<",
                                "value": 1,
                                "unit": "treatment(s) in last 3 years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Other primary non-hematologic malignancies or solid tumor",
                                "criterion": "other primary non-hematologic malignancy or solid tumor",
                                "requirement": {
                                    "requirement_type": "history",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "treated with curative intent",
                                "criterion": "treatment intent for other primary non-hematologic malignancy or solid tumor",
                                "requirement": {
                                    "requirement_type": "treatment_intent",
                                    "expected_value": "curative"
                                }
                            },
                            {
                                "exact_snippets": "no known active disease",
                                "criterion": "active disease status of other primary non-hematologic malignancy or solid tumor",
                                "requirement": {
                                    "requirement_type": "active_disease",
                                    "expected_value": false
                                }
                            },
                            {
                                "exact_snippets": "no treatment administered during the last 3 years prior to registration",
                                "criterion": "recent treatment for other primary non-hematologic malignancy or solid tumor",
                                "requirement": {
                                    "requirement_type": "treatment_within_timeframe",
                                    "expected_value": {
                                        "operator": "<",
                                        "value": 1,
                                        "unit": "treatment(s) in last 3 years"
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Treatment with medications known to cause corrected QT (QTc) interval prolongation within 7 days of study day 1 is not permitted unless approved by the sponsor; use of ondansetron is permitted for treatment of nausea and vomiting",
                "criterions": [
                    {
                        "exact_snippets": "Treatment with medications known to cause corrected QT (QTc) interval prolongation within 7 days of study day 1 is not permitted unless approved by the sponsor",
                        "criterion": "treatment with medications known to cause QTc interval prolongation",
                        "requirement": {
                            "requirement_type": "exposure_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Treatment with medications known to cause corrected QT (QTc) interval prolongation within 7 days of study day 1 is not permitted unless approved by the sponsor",
                        "criterion": "treatment with medications known to cause QTc interval prolongation",
                        "requirement": {
                            "requirement_type": "permitted",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "Treatment with medications known to cause corrected QT (QTc) interval prolongation within 7 days of study day 1 is not permitted unless approved by the sponsor",
                        "criterion": "treatment with medications known to cause QTc interval prolongation",
                        "requirement": {
                            "requirement_type": "exception",
                            "expected_value": "unless approved by the sponsor"
                        }
                    },
                    {
                        "exact_snippets": "use of ondansetron is permitted for treatment of nausea and vomiting",
                        "criterion": "use of ondansetron for treatment of nausea and vomiting",
                        "requirement": {
                            "requirement_type": "permitted",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "and_criteria": [
                                    {
                                        "and_criteria": [
                                            {
                                                "exact_snippets": "Treatment with medications known to cause corrected QT (QTc) interval prolongation within 7 days of study day 1 is not permitted unless approved by the sponsor",
                                                "criterion": "treatment with medications known to cause QTc interval prolongation",
                                                "requirement": {
                                                    "requirement_type": "exposure_within_timeframe",
                                                    "expected_value": {
                                                        "operator": "<=",
                                                        "value": 7,
                                                        "unit": "days"
                                                    }
                                                }
                                            },
                                            {
                                                "exact_snippets": "Treatment with medications known to cause corrected QT (QTc) interval prolongation within 7 days of study day 1 is not permitted unless approved by the sponsor",
                                                "criterion": "treatment with medications known to cause QTc interval prolongation",
                                                "requirement": {
                                                    "requirement_type": "permitted",
                                                    "expected_value": false
                                                }
                                            }
                                        ]
                                    },
                                    {
                                        "exact_snippets": "Treatment with medications known to cause corrected QT (QTc) interval prolongation within 7 days of study day 1 is not permitted unless approved by the sponsor",
                                        "criterion": "treatment with medications known to cause QTc interval prolongation",
                                        "requirement": {
                                            "requirement_type": "exception",
                                            "expected_value": "unless approved by the sponsor"
                                        }
                                    }
                                ]
                            },
                            {
                                "not_criteria": {
                                    "exact_snippets": "use of ondansetron is permitted for treatment of nausea and vomiting",
                                    "criterion": "use of ondansetron for treatment of nausea and vomiting",
                                    "requirement": {
                                        "requirement_type": "permitted",
                                        "expected_value": true
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* All subjects must agree to stop the use of all herbal medicines (e.g., St. John's wort), and supplements, within the 10 days prior to receiving the first dose of AMG 232 (KRT-232), and during the protocol AMG 232 (KRT-232) treatment (weeks 1-5); subjects may renew the use of the above at week 6; standard adult multi-vitamin is allowed",
                "criterions": [
                    {
                        "exact_snippets": "All subjects must agree to stop the use of all herbal medicines (e.g., St. John's wort), and supplements, within the 10 days prior to receiving the first dose of AMG 232 (KRT-232), and during the protocol AMG 232 (KRT-232) treatment (weeks 1-5)",
                        "criterion": "use of herbal medicines and supplements",
                        "requirement": {
                            "requirement_type": "cessation",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "All subjects must agree to stop the use of all herbal medicines (e.g., St. John's wort), and supplements, within the 10 days prior to receiving the first dose of AMG 232 (KRT-232), and during the protocol AMG 232 (KRT-232) treatment (weeks 1-5)",
                        "criterion": "use of herbal medicines and supplements",
                        "requirement": {
                            "requirement_type": "cessation_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": -10,
                                        "unit": "days before first dose"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "All subjects must agree to stop the use of all herbal medicines (e.g., St. John's wort), and supplements, within the 10 days prior to receiving the first dose of AMG 232 (KRT-232), and during the protocol AMG 232 (KRT-232) treatment (weeks 1-5)",
                        "criterion": "use of herbal medicines and supplements",
                        "requirement": {
                            "requirement_type": "cessation_duration",
                            "expected_value": "during protocol treatment (weeks 1-5)"
                        }
                    },
                    {
                        "exact_snippets": "subjects may renew the use of the above at week 6",
                        "criterion": "use of herbal medicines and supplements",
                        "requirement": {
                            "requirement_type": "resumption_time",
                            "expected_value": "week 6"
                        }
                    },
                    {
                        "exact_snippets": "standard adult multi-vitamin is allowed",
                        "criterion": "use of standard adult multi-vitamin",
                        "requirement": {
                            "requirement_type": "allowance",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "not_criteria": {
                            "and_criteria": [
                                {
                                    "exact_snippets": "All subjects must agree to stop the use of all herbal medicines (e.g., St. John's wort), and supplements, within the 10 days prior to receiving the first dose of AMG 232 (KRT-232), and during the protocol AMG 232 (KRT-232) treatment (weeks 1-5)",
                                    "criterion": "use of herbal medicines and supplements",
                                    "requirement": {
                                        "requirement_type": "cessation",
                                        "expected_value": true
                                    }
                                },
                                {
                                    "exact_snippets": "All subjects must agree to stop the use of all herbal medicines (e.g., St. John's wort), and supplements, within the 10 days prior to receiving the first dose of AMG 232 (KRT-232), and during the protocol AMG 232 (KRT-232) treatment (weeks 1-5)",
                                    "criterion": "use of herbal medicines and supplements",
                                    "requirement": {
                                        "requirement_type": "cessation_timeframe",
                                        "expected_value": {
                                            "comparisons": [
                                                {
                                                    "operator": "<=",
                                                    "value": -10,
                                                    "unit": "days before first dose"
                                                }
                                            ]
                                        }
                                    }
                                },
                                {
                                    "exact_snippets": "All subjects must agree to stop the use of all herbal medicines (e.g., St. John's wort), and supplements, within the 10 days prior to receiving the first dose of AMG 232 (KRT-232), and during the protocol AMG 232 (KRT-232) treatment (weeks 1-5)",
                                    "criterion": "use of herbal medicines and supplements",
                                    "requirement": {
                                        "requirement_type": "cessation_duration",
                                        "expected_value": "during protocol treatment (weeks 1-5)"
                                    }
                                },
                                {
                                    "exact_snippets": "subjects may renew the use of the above at week 6",
                                    "criterion": "use of herbal medicines and supplements",
                                    "requirement": {
                                        "requirement_type": "resumption_time",
                                        "expected_value": "week 6"
                                    }
                                },
                                {
                                    "exact_snippets": "standard adult multi-vitamin is allowed",
                                    "criterion": "use of standard adult multi-vitamin",
                                    "requirement": {
                                        "requirement_type": "allowance",
                                        "expected_value": true
                                    }
                                }
                            ]
                        }
                    },
                    {
                        "not_criteria": {
                            "and_criteria": [
                                {
                                    "exact_snippets": "standard adult multi-vitamin is allowed",
                                    "criterion": "use of standard adult multi-vitamin",
                                    "requirement": {
                                        "requirement_type": "allowance",
                                        "expected_value": true
                                    }
                                }
                            ]
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PRIOR TO STEP 1 REGISTRATION EXCLUSION CRITERIA",
                "criterions": []
            },
            "logical_structure": {
                "and_criteria": []
            }
        },
        {
            "identified_line": {
                "line": "* History of allergic reactions attributed to compounds of similar chemical or biologic composition to AMG 232 (KRT-232)",
                "criterions": [
                    {
                        "exact_snippets": "History of allergic reactions attributed to compounds of similar chemical or biologic composition to AMG 232 (KRT-232)",
                        "criterion": "allergic reactions to compounds of similar chemical or biologic composition to AMG 232 (KRT-232)",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "History of allergic reactions attributed to compounds of similar chemical or biologic composition to AMG 232 (KRT-232)",
                        "criterion": "allergic reactions to compounds of similar chemical or biologic composition to AMG 232 (KRT-232)",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields",
                "criterions": [
                    {
                        "exact_snippets": "Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields",
                        "criterion": "prior radiotherapy to the region of the study cancer",
                        "requirement": {
                            "requirement_type": "overlap of radiation therapy fields",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields",
                        "criterion": "prior radiotherapy to the region of the study cancer",
                        "requirement": {
                            "requirement_type": "overlap of radiation therapy fields",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard PCR-based test",
                "criterions": [
                    {
                        "exact_snippets": "CD4 count above 250 cells/mcL",
                        "criterion": "CD4 count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 250,
                                "unit": "cells/mcL"
                            }
                        }
                    },
                    {
                        "exact_snippets": "undetectable HIV viral load on standard PCR-based test",
                        "criterion": "HIV viral load",
                        "requirement": {
                            "requirement_type": "detectability",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "CD4 count above 250 cells/mcL",
                        "criterion": "CD4 count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 250,
                                "unit": "cells/mcL"
                            }
                        }
                    },
                    {
                        "exact_snippets": "undetectable HIV viral load on standard PCR-based test",
                        "criterion": "HIV viral load",
                        "requirement": {
                            "requirement_type": "detectability",
                            "expected_value": false
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* HIV testing is not required",
                "criterions": [
                    {
                        "exact_snippets": "HIV testing is not required",
                        "criterion": "HIV testing",
                        "requirement": {
                            "requirement_type": "requirement",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "HIV testing is not required",
                        "criterion": "HIV testing",
                        "requirement": {
                            "requirement_type": "requirement",
                            "expected_value": false
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Prior systemic chemotherapy for the study cancer (sarcoma); note that prior chemotherapy for a different cancer is allowable; however, unresolved toxicities from prior anti-tumor therapy, defined as not having resolved to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 grade 0 or 1, or to levels dictated in the eligibility criteria with the exception of alopecia (grade 2 or 3 toxicities from prior anti-tumor therapy that are considered irreversible [defined as having been present and stable for > 6 months], such as ifosfamide-related proteinuria, may be allowed if they are not otherwise described in the exclusion criteria AND there is agreement to allow by both the investigator and sponsor)",
                "criterions": [
                    {
                        "exact_snippets": "Prior systemic chemotherapy for the study cancer (sarcoma)",
                        "criterion": "prior systemic chemotherapy for sarcoma",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "unresolved toxicities from prior anti-tumor therapy, defined as not having resolved to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 grade 0 or 1, or to levels dictated in the eligibility criteria",
                        "criterion": "toxicities from prior anti-tumor therapy",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">",
                                        "value": 1,
                                        "unit": "CTCAE v5.0 grade"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "alopecia (grade 2 or 3 toxicities from prior anti-tumor therapy that are considered irreversible [defined as having been present and stable for > 6 months], such as ifosfamide-related proteinuria, may be allowed if they are not otherwise described in the exclusion criteria AND there is agreement to allow by both the investigator and sponsor",
                        "criterion": "irreversible grade 2 or 3 toxicities from prior anti-tumor therapy (e.g., ifosfamide-related proteinuria)",
                        "requirement": {
                            "requirement_type": "irreversibility",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "alopecia (grade 2 or 3 toxicities from prior anti-tumor therapy that are considered irreversible [defined as having been present and stable for > 6 months], such as ifosfamide-related proteinuria, may be allowed if they are not otherwise described in the exclusion criteria AND there is agreement to allow by both the investigator and sponsor",
                        "criterion": "irreversible grade 2 or 3 toxicities from prior anti-tumor therapy (e.g., ifosfamide-related proteinuria)",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "alopecia (grade 2 or 3 toxicities from prior anti-tumor therapy that are considered irreversible [defined as having been present and stable for > 6 months], such as ifosfamide-related proteinuria, may be allowed if they are not otherwise described in the exclusion criteria AND there is agreement to allow by both the investigator and sponsor",
                        "criterion": "irreversible grade 2 or 3 toxicities from prior anti-tumor therapy (e.g., ifosfamide-related proteinuria)",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 2,
                                        "unit": "CTCAE v5.0 grade"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": "CTCAE v5.0 grade"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "alopecia (grade 2 or 3 toxicities from prior anti-tumor therapy that are considered irreversible [defined as having been present and stable for > 6 months], such as ifosfamide-related proteinuria, may be allowed if they are not otherwise described in the exclusion criteria AND there is agreement to allow by both the investigator and sponsor",
                        "criterion": "irreversible grade 2 or 3 toxicities from prior anti-tumor therapy (e.g., ifosfamide-related proteinuria)",
                        "requirement": {
                            "requirement_type": "not_excluded",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "alopecia (grade 2 or 3 toxicities from prior anti-tumor therapy that are considered irreversible [defined as having been present and stable for > 6 months], such as ifosfamide-related proteinuria, may be allowed if they are not otherwise described in the exclusion criteria AND there is agreement to allow by both the investigator and sponsor",
                        "criterion": "irreversible grade 2 or 3 toxicities from prior anti-tumor therapy (e.g., ifosfamide-related proteinuria)",
                        "requirement": {
                            "requirement_type": "investigator_and_sponsor_agreement",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Prior systemic chemotherapy for the study cancer (sarcoma)",
                        "criterion": "prior systemic chemotherapy for sarcoma",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "unresolved toxicities from prior anti-tumor therapy, defined as not having resolved to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 grade 0 or 1, or to levels dictated in the eligibility criteria",
                                "criterion": "toxicities from prior anti-tumor therapy",
                                "requirement": {
                                    "requirement_type": "severity",
                                    "expected_value": {
                                        "comparisons": [
                                            {
                                                "operator": ">",
                                                "value": 1,
                                                "unit": "CTCAE v5.0 grade"
                                            }
                                        ]
                                    }
                                }
                            },
                            {
                                "not_criteria": {
                                    "and_criteria": [
                                        {
                                            "exact_snippets": "alopecia (grade 2 or 3 toxicities from prior anti-tumor therapy that are considered irreversible [defined as having been present and stable for > 6 months], such as ifosfamide-related proteinuria, may be allowed if they are not otherwise described in the exclusion criteria AND there is agreement to allow by both the investigator and sponsor",
                                            "criterion": "irreversible grade 2 or 3 toxicities from prior anti-tumor therapy (e.g., ifosfamide-related proteinuria)",
                                            "requirement": {
                                                "requirement_type": "irreversibility",
                                                "expected_value": true
                                            }
                                        },
                                        {
                                            "exact_snippets": "alopecia (grade 2 or 3 toxicities from prior anti-tumor therapy that are considered irreversible [defined as having been present and stable for > 6 months], such as ifosfamide-related proteinuria, may be allowed if they are not otherwise described in the exclusion criteria AND there is agreement to allow by both the investigator and sponsor",
                                            "criterion": "irreversible grade 2 or 3 toxicities from prior anti-tumor therapy (e.g., ifosfamide-related proteinuria)",
                                            "requirement": {
                                                "requirement_type": "duration",
                                                "expected_value": {
                                                    "operator": ">",
                                                    "value": 6,
                                                    "unit": "months"
                                                }
                                            }
                                        },
                                        {
                                            "exact_snippets": "alopecia (grade 2 or 3 toxicities from prior anti-tumor therapy that are considered irreversible [defined as having been present and stable for > 6 months], such as ifosfamide-related proteinuria, may be allowed if they are not otherwise described in the exclusion criteria AND there is agreement to allow by both the investigator and sponsor",
                                            "criterion": "irreversible grade 2 or 3 toxicities from prior anti-tumor therapy (e.g., ifosfamide-related proteinuria)",
                                            "requirement": {
                                                "requirement_type": "severity",
                                                "expected_value": {
                                                    "comparisons": [
                                                        {
                                                            "operator": ">=",
                                                            "value": 2,
                                                            "unit": "CTCAE v5.0 grade"
                                                        },
                                                        {
                                                            "operator": "<=",
                                                            "value": 3,
                                                            "unit": "CTCAE v5.0 grade"
                                                        }
                                                    ]
                                                }
                                            }
                                        },
                                        {
                                            "exact_snippets": "alopecia (grade 2 or 3 toxicities from prior anti-tumor therapy that are considered irreversible [defined as having been present and stable for > 6 months], such as ifosfamide-related proteinuria, may be allowed if they are not otherwise described in the exclusion criteria AND there is agreement to allow by both the investigator and sponsor",
                                            "criterion": "irreversible grade 2 or 3 toxicities from prior anti-tumor therapy (e.g., ifosfamide-related proteinuria)",
                                            "requirement": {
                                                "requirement_type": "not_excluded",
                                                "expected_value": true
                                            }
                                        },
                                        {
                                            "exact_snippets": "alopecia (grade 2 or 3 toxicities from prior anti-tumor therapy that are considered irreversible [defined as having been present and stable for > 6 months], such as ifosfamide-related proteinuria, may be allowed if they are not otherwise described in the exclusion criteria AND there is agreement to allow by both the investigator and sponsor",
                                            "criterion": "irreversible grade 2 or 3 toxicities from prior anti-tumor therapy (e.g., ifosfamide-related proteinuria)",
                                            "requirement": {
                                                "requirement_type": "investigator_and_sponsor_agreement",
                                                "expected_value": true
                                            }
                                        }
                                    ]
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Females who are pregnant or breastfeeding",
                "criterions": [
                    {
                        "exact_snippets": "Females who are pregnant",
                        "criterion": "pregnancy status",
                        "requirement": {
                            "requirement_type": "pregnant",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Females who are ... breastfeeding",
                        "criterion": "breastfeeding status",
                        "requirement": {
                            "requirement_type": "breastfeeding",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Females who are pregnant",
                        "criterion": "pregnancy status",
                        "requirement": {
                            "requirement_type": "pregnant",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Females who are ... breastfeeding",
                        "criterion": "breastfeeding status",
                        "requirement": {
                            "requirement_type": "breastfeeding",
                            "expected_value": true
                        }
                    }
                ]
            }
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "identified_line": {
                "line": "* Imaging of the primary tumor by MRI and/or computed tomography (CT) with or without contrast and/or positron emission tomography (PET)/CT within 30 days prior to registration;",
                "criterions": [
                    {
                        "exact_snippets": "Imaging of the primary tumor by MRI and/or computed tomography (CT) with or without contrast and/or positron emission tomography (PET)/CT within 30 days prior to registration",
                        "criterion": "imaging of the primary tumor",
                        "requirement": {
                            "requirement_type": "modality",
                            "expected_value": [
                                "MRI",
                                "computed tomography (CT)",
                                "positron emission tomography (PET)/CT"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "Imaging of the primary tumor by MRI and/or computed tomography (CT) with or without contrast and/or positron emission tomography (PET)/CT within 30 days prior to registration",
                        "criterion": "imaging of the primary tumor",
                        "requirement": {
                            "requirement_type": "contrast usage",
                            "expected_value": [
                                "with contrast",
                                "without contrast"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "Imaging of the primary tumor by MRI and/or computed tomography (CT) with or without contrast and/or positron emission tomography (PET)/CT within 30 days prior to registration",
                        "criterion": "imaging of the primary tumor",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days prior to registration"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Staging workup evaluated by chest CT and/or PET/CT showing no distant metastasis within 30 days prior to registration",
                "criterions": [
                    {
                        "exact_snippets": "Staging workup evaluated by chest CT and/or PET/CT",
                        "criterion": "staging workup by imaging",
                        "requirement": {
                            "requirement_type": "modality",
                            "expected_value": [
                                "chest CT",
                                "PET/CT"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "Staging workup evaluated by chest CT and/or PET/CT",
                        "criterion": "staging workup by imaging",
                        "requirement": {
                            "requirement_type": "completion",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "showing no distant metastasis",
                        "criterion": "distant metastasis",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "within 30 days prior to registration",
                        "criterion": "timing of imaging",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days prior to registration"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Females of child-bearing potential must have a negative serum pregnancy test within 7 days prior to registration; exceptions: females not of child-bearing potential due to surgical sterilization (at least 6 weeks following tubal ligation, hysterectomy, or surgical bilateral oophorectomy with or without hysterectomy) confirmed by medical history; or female after menopause",
                "criterions": [
                    {
                        "exact_snippets": "Females of child-bearing potential must have a negative serum pregnancy test within 7 days prior to registration",
                        "criterion": "serum pregnancy test",
                        "requirement": {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        }
                    },
                    {
                        "exact_snippets": "Females of child-bearing potential must have a negative serum pregnancy test within 7 days prior to registration",
                        "criterion": "serum pregnancy test",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "within 7 days prior to registration"
                        }
                    },
                    {
                        "exact_snippets": "females not of child-bearing potential due to surgical sterilization (at least 6 weeks following tubal ligation, hysterectomy, or surgical bilateral oophorectomy with or without hysterectomy) confirmed by medical history",
                        "criterion": "surgical sterilization",
                        "requirement": {
                            "requirement_type": "procedure",
                            "expected_value": [
                                "tubal ligation",
                                "hysterectomy",
                                "surgical bilateral oophorectomy"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "females not of child-bearing potential due to surgical sterilization (at least 6 weeks following tubal ligation, hysterectomy, or surgical bilateral oophorectomy with or without hysterectomy) confirmed by medical history",
                        "criterion": "surgical sterilization",
                        "requirement": {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "females not of child-bearing potential due to surgical sterilization (at least 6 weeks following tubal ligation, hysterectomy, or surgical bilateral oophorectomy with or without hysterectomy) confirmed by medical history",
                        "criterion": "surgical sterilization",
                        "requirement": {
                            "requirement_type": "confirmation",
                            "expected_value": "confirmed by medical history"
                        }
                    },
                    {
                        "exact_snippets": "female after menopause",
                        "criterion": "menopausal status",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": "postmenopausal"
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        }
    ],
    "failed_exclusion": [
        {
            "identified_line": {
                "line": "* Definitive clinical or radiologic evidence of metastatic disease; indeterminant lung nodules less than 8 mm are acceptable",
                "criterions": [
                    {
                        "exact_snippets": "Definitive clinical or radiologic evidence of metastatic disease",
                        "criterion": "metastatic disease",
                        "requirement": {
                            "requirement_type": "evidence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Definitive clinical or radiologic evidence of metastatic disease",
                        "criterion": "metastatic disease",
                        "requirement": {
                            "requirement_type": "evidence_type",
                            "expected_value": [
                                "clinical",
                                "radiologic"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "indeterminant lung nodules less than 8 mm are acceptable",
                        "criterion": "indeterminant lung nodules",
                        "requirement": {
                            "requirement_type": "size",
                            "expected_value": {
                                "operator": "<",
                                "value": 8,
                                "unit": "mm"
                            }
                        }
                    },
                    {
                        "exact_snippets": "indeterminant lung nodules less than 8 mm are acceptable",
                        "criterion": "indeterminant lung nodules",
                        "requirement": {
                            "requirement_type": "acceptability",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Clinically significant bleeding within 4 weeks of screening, current use of warfarin, factor Xa inhibitors, and direct thrombin inhibitors unless these medications can be safely discontinued 14 days prior to AMG-232 (KRT-232) administration; Note: low molecular weight heparin and prophylactic low dose warfarin are permitted; PT/PTT must meet the inclusion criteria; subjects taking warfarin must have their INR followed closely",
                "criterions": [
                    {
                        "exact_snippets": "Clinically significant bleeding within 4 weeks of screening",
                        "criterion": "clinically significant bleeding",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Clinically significant bleeding within 4 weeks of screening",
                        "criterion": "clinically significant bleeding",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "current use of warfarin, factor Xa inhibitors, and direct thrombin inhibitors unless these medications can be safely discontinued 14 days prior to AMG-232 (KRT-232) administration",
                        "criterion": "use of anticoagulant medications",
                        "requirement": {
                            "requirement_type": "current use",
                            "expected_value": [
                                "warfarin",
                                "factor Xa inhibitors",
                                "direct thrombin inhibitors"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "current use of warfarin, factor Xa inhibitors, and direct thrombin inhibitors unless these medications can be safely discontinued 14 days prior to AMG-232 (KRT-232) administration",
                        "criterion": "use of anticoagulant medications",
                        "requirement": {
                            "requirement_type": "discontinuation before AMG-232 (KRT-232) administration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "PT/PTT must meet the inclusion criteria",
                        "criterion": "PT/PTT",
                        "requirement": {
                            "requirement_type": "meets inclusion criteria",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "subjects taking warfarin must have their INR followed closely",
                        "criterion": "INR monitoring for subjects on warfarin",
                        "requirement": {
                            "requirement_type": "monitoring",
                            "expected_value": "closely followed"
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* The patient has a serious cardiac condition, such as congestive heart failure; New York Heart Association class II/ III/IV heart disease; unstable angina pectoris, cardiac stenting within 6 months of enrollment; myocardial infarction within the last 3 months; valvulopathy that is severe, moderate, or deemed clinically significant; or arrhythmias that are symptomatic or require treatment",
                "criterions": [
                    {
                        "exact_snippets": "serious cardiac condition",
                        "criterion": "cardiac condition",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": "serious"
                        }
                    },
                    {
                        "exact_snippets": "congestive heart failure",
                        "criterion": "congestive heart failure",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "New York Heart Association class II/ III/IV heart disease",
                        "criterion": "New York Heart Association class heart disease",
                        "requirement": {
                            "requirement_type": "class",
                            "expected_value": [
                                "II",
                                "III",
                                "IV"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "unstable angina pectoris",
                        "criterion": "unstable angina pectoris",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "cardiac stenting within 6 months of enrollment",
                        "criterion": "cardiac stenting",
                        "requirement": {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "myocardial infarction within the last 3 months",
                        "criterion": "myocardial infarction",
                        "requirement": {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "valvulopathy that is severe, moderate, or deemed clinically significant",
                        "criterion": "valvulopathy",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": [
                                "severe",
                                "moderate",
                                "clinically significant"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "arrhythmias that are symptomatic or require treatment",
                        "criterion": "arrhythmias",
                        "requirement": {
                            "requirement_type": "symptomatic",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "arrhythmias that are symptomatic or require treatment",
                        "criterion": "arrhythmias",
                        "requirement": {
                            "requirement_type": "require treatment",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* All subjects must agree to stop the use of any known CYP2C8 substrates with a narrow therapeutic window within the 14 days prior to receiving the first dose of AMG 232 (KRT-232) and during protocol AMG 232 (KRT-232) treatment (weeks 1-5)",
                "criterions": [
                    {
                        "exact_snippets": "All subjects must agree to stop the use of any known CYP2C8 substrates with a narrow therapeutic window within the 14 days prior to receiving the first dose of AMG 232 (KRT-232) and during protocol AMG 232 (KRT-232) treatment (weeks 1-5)",
                        "criterion": "use of known CYP2C8 substrates with a narrow therapeutic window",
                        "requirement": {
                            "requirement_type": "cessation",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "All subjects must agree to stop the use of any known CYP2C8 substrates with a narrow therapeutic window within the 14 days prior to receiving the first dose of AMG 232 (KRT-232) and during protocol AMG 232 (KRT-232) treatment (weeks 1-5)",
                        "criterion": "use of known CYP2C8 substrates with a narrow therapeutic window",
                        "requirement": {
                            "requirement_type": "timeframe",
                            "expected_value": [
                                "within the 14 days prior to receiving the first dose of AMG 232 (KRT-232)",
                                "during protocol AMG 232 (KRT-232) treatment (weeks 1-5)"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* All subjects must agree to stop the use of any known CYP3A4 substrates with narrow therapeutic window (such as alfentanil, astemizole, cisapride, dihydroergotamine, pimozide, quinidine, sirolimus, or terfenadine; within the 14 days prior to receiving the first dose of AMG 232 (KRT-232) and during protocol AMG 232 (KRT-232) treatment (weeks 1-5); other medications (such as fentanyl and oxycodone) may be allowed per investigator's assessment/evaluation",
                "criterions": [
                    {
                        "exact_snippets": "All subjects must agree to stop the use of any known CYP3A4 substrates with narrow therapeutic window (such as alfentanil, astemizole, cisapride, dihydroergotamine, pimozide, quinidine, sirolimus, or terfenadine; within the 14 days prior to receiving the first dose of AMG 232 (KRT-232) and during protocol AMG 232 (KRT-232) treatment (weeks 1-5)",
                        "criterion": "use of CYP3A4 substrates with narrow therapeutic window",
                        "requirement": {
                            "requirement_type": "cessation",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "All subjects must agree to stop the use of any known CYP3A4 substrates with narrow therapeutic window (such as alfentanil, astemizole, cisapride, dihydroergotamine, pimozide, quinidine, sirolimus, or terfenadine; within the 14 days prior to receiving the first dose of AMG 232 (KRT-232) and during protocol AMG 232 (KRT-232) treatment (weeks 1-5)",
                        "criterion": "use of CYP3A4 substrates with narrow therapeutic window",
                        "requirement": {
                            "requirement_type": "timeframe",
                            "expected_value": [
                                "within the 14 days prior to receiving the first dose of AMG 232 (KRT-232)",
                                "during protocol AMG 232 (KRT-232) treatment (weeks 1-5)"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        }
    ],
    "failed_miscellaneous": []
}